Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AKTX
- Price
- 1.12
- Stock movement down
- -0.02 (-2.62%)
- Company name
- Akari Therapeutics PLC
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 30.17M
- Ent value
- 37.35M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -37.14%
- 1 year return
- -74.31%
- 3 year return
- -68.64%
- 5 year return
- -52.23%
- 10 year return
- -39.01%
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AKTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 32.61M |
| EPS (TTM) | -1.60 |
| FCF per share (TTM) | -0.86 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -13.00K |
| Operating income (TTM) | -20.16M |
| Net income (TTM) | -19.52M |
| EPS (TTM) | -1.60 |
| EPS (1y forward) | -0.40 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.25M |
| Net receivables | 0.00 |
| Total current assets | 2.73M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 2.73M |
| Accounts payable | 4.78M |
| Short/Current long term debt | 1.00M |
| Total current liabilities | 9.43M |
| Total liabilities | 9.43M |
| Shareholder's equity | -6.69M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -10.43M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -10.43M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -714.11% |
| Return on Invested Capital | 342.88% |
| Cash Return on Invested Capital | 183.20% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.96 |
| Daily high | 0.97 |
| Daily low | 0.91 |
| Daily Volume | 43K |
| All-time high | 5000.00 |
| 1y analyst estimate | 6.00 |
| Beta | 0.23 |
| EPS (TTM) | -1.60 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| AKTX | S&P500 | |
| Current price drop from All-time high | -99.98% | -1.46% |
| Highest price drop | -99.98% | -56.47% |
| Date of highest drop | 28 Feb 2025 | 9 Mar 2009 |
| Avg drop from high | -96.29% | -10.99% |
| Avg time to new high | 1430 days | 12 days |
| Max time to new high | 2860 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
30.17M
Marketcap category
Small-cap
Description
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Employees
8
Website
Investor relations
-
SEC filings
CEO
Clive Stuart Richardson
Country
USA
City
London
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page